Wedbush Reiterates an 'Outperform' on Medivation (MDVN); Raising PT on Early Approval
Tweet Send to a FriendGet Alerts MDVN Hot Sheet
Price: $47.53 --0%
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 31 | New: 11
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 31 | New: 11
Trade MDVN Now!
Wedbush reiterates an 'Outperform' on Medivation (NASDAQ: MDVN) price target of $118.00 (from $100.00).
Analyst, David M. Nierengarten, said, "MDVN and partner Astellas will launch in mid-September, and priced Xtandi at $7450/month, a premium to our estimated $6500/month, and higher than Zytiga (NYSE: JNJ). While a premium to Zytiga was expected, pricing came in a bit higher than we had estimated."
"We estimate the following in US sales of Xtandi: $18.9M, $43.6M, $55.4M, and $98.9M (per quarter in the first year of launch). While we expect that ultimately Xtandi will surpass Zytiga in sales and the pre-chemotherapy data for Xtandi (H1:14) will make it the market leader, initial uptake will likely lag Zytiga’s launch because oncologists are reluctant to switch patients to new therapies unless the patient progresses."
FY12 EPS estimate lowered from (2.11) to (2.20) and FY13 raised from (2.66) to (2.57)
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $104.86 yesterday, with a 52 week range of $15.49-$105.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, David M. Nierengarten, said, "MDVN and partner Astellas will launch in mid-September, and priced Xtandi at $7450/month, a premium to our estimated $6500/month, and higher than Zytiga (NYSE: JNJ). While a premium to Zytiga was expected, pricing came in a bit higher than we had estimated."
"We estimate the following in US sales of Xtandi: $18.9M, $43.6M, $55.4M, and $98.9M (per quarter in the first year of launch). While we expect that ultimately Xtandi will surpass Zytiga in sales and the pre-chemotherapy data for Xtandi (H1:14) will make it the market leader, initial uptake will likely lag Zytiga’s launch because oncologists are reluctant to switch patients to new therapies unless the patient progresses."
FY12 EPS estimate lowered from (2.11) to (2.20) and FY13 raised from (2.66) to (2.57)
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $104.86 yesterday, with a 52 week range of $15.49-$105.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
- Wells Fargo Downgrades Ruby Tuesday (RT) to Market Perform
- Jefferies Downgrades Bed Bath & Beyond (BBBY) to Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
